Neuroscience
From the AP, via Yahoo! News:
Largest-Ever Alzheimer's Drug Trial Begins
By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET
SAN FRANCISCO - It's tragedy enough that Pat Williams' mother has Alzheimer's disease. But Williams is also terrified because her chances of inheriting the disease are much better than average. So Williams eagerly enrolled her 90-year-old mother last year in a massive, 1,600-patient, 18-month clinical trial testing an experimental drug made by the biotechnology company Myriad Genetics Inc.
The drug, called Flurizan, slowed the mind-robbing disease in some of the 128 patients with mild Alzheimer's participating in a smaller test.
Based on those results, the company has gambled millions of research dollars on the largest-ever Alzheimer's drug trial. It aims to win an intense, international race among several biotech companies to find the first effective treatment to at least slow the disease's progression in the 4.5 million Americans who suffer from it.
Analysts predict the market for such a drug could reach $4 billion annually by 2013 and success for Myriad would lift the company's fortunes considerably. The Salt Lake City company is now best known for drilling deep into the Mormon community's detailed genetic history to develop a popular breast cancer test.
Myriad's Alzheimer's drug wasn't effective for patients with moderate forms of the disease, so the company is targeting patients who have just been diagnosed. Scientists are also using the latest in brain imaging and genetic technology to develop tests to find people like Williams who have above-average chances of coming down the disease.
Read the full report
-
Anthony H. Risser | neuroscience | neuropsychology | brain |
alzheimer disease
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease: Phase Ii Gammagard Findings
A report from the Alzheimer's Association International Conference (AAIC) in Vancouver: Alzheimer's drug IVIg could halt sufferers' decline Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory...
- Fda: Alzheimer Disease, Aricept (donepezil Hydrochloride)
From the FDA last week: FDA Approves Expanded Use of Treatment for Patients With Severe Alzheimer's Disease FOR IMMEDIATE RELEASE P06-168 October 13, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA...
- Legal World: Amgen, Gdnf Clinical Trial, And Parkinson Disease
From The New York Times, concerning glial cell line-derived neurotrophic factor (GDNF):Judge Rejects Patients' Suit to Get Test Drug By ANDREW POLLACK The New York Times Published: June 8, 2005 A federal judge has denied a request by two people...
- Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug By ANDREW POLLACK New York Times Published: January 22, 2005 Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...
Neuroscience
Business World: Myriad Genetics, Flurizan (MPC-7869), and Alzheimer Disease
From the AP, via Yahoo! News:
Largest-Ever Alzheimer's Drug Trial Begins
By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET
SAN FRANCISCO - It's tragedy enough that Pat Williams' mother has Alzheimer's disease. But Williams is also terrified because her chances of inheriting the disease are much better than average. So Williams eagerly enrolled her 90-year-old mother last year in a massive, 1,600-patient, 18-month clinical trial testing an experimental drug made by the biotechnology company Myriad Genetics Inc.
The drug, called Flurizan, slowed the mind-robbing disease in some of the 128 patients with mild Alzheimer's participating in a smaller test.
Based on those results, the company has gambled millions of research dollars on the largest-ever Alzheimer's drug trial. It aims to win an intense, international race among several biotech companies to find the first effective treatment to at least slow the disease's progression in the 4.5 million Americans who suffer from it.
Analysts predict the market for such a drug could reach $4 billion annually by 2013 and success for Myriad would lift the company's fortunes considerably. The Salt Lake City company is now best known for drilling deep into the Mormon community's detailed genetic history to develop a popular breast cancer test.
Myriad's Alzheimer's drug wasn't effective for patients with moderate forms of the disease, so the company is targeting patients who have just been diagnosed. Scientists are also using the latest in brain imaging and genetic technology to develop tests to find people like Williams who have above-average chances of coming down the disease.
Read the full report
-
Anthony H. Risser | neuroscience | neuropsychology | brain |
alzheimer disease
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease: Phase Ii Gammagard Findings
A report from the Alzheimer's Association International Conference (AAIC) in Vancouver: Alzheimer's drug IVIg could halt sufferers' decline Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory...
- Fda: Alzheimer Disease, Aricept (donepezil Hydrochloride)
From the FDA last week: FDA Approves Expanded Use of Treatment for Patients With Severe Alzheimer's Disease FOR IMMEDIATE RELEASE P06-168 October 13, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA...
- Legal World: Amgen, Gdnf Clinical Trial, And Parkinson Disease
From The New York Times, concerning glial cell line-derived neurotrophic factor (GDNF):Judge Rejects Patients' Suit to Get Test Drug By ANDREW POLLACK The New York Times Published: June 8, 2005 A federal judge has denied a request by two people...
- Reminyl (galantamine Hydrobromide) (continued)
Safety Concerns Reported on J.& J. Alzheimer's Drug By ANDREW POLLACK New York Times Published: January 22, 2005 Regulators are reviewing the safety of the Alzheimer's disease drug Reminyl after data from two clinical trials indicated...